中文版正在生成中，先为你展示英文版分析。
AI核心结论
Eli Lilly delivered exceptional FY2025 results with revenue surging 44.7% to $65.2B and net income nearly doubling to $20.6B, driven by explosive demand for its GLP-1 medicines Mounjaro and Zepbound.
营业收入
$65.18B
同比 ++44.70%
每股收益（基本）
$23.00
同比 ++95.58%
提交于 · 解读更新于 · 来源: SEC EDGAR 10-K 原文
ELI LILLY & Co (LLY) FY2025 营收 $65.18B，同比增长 44.7%。 净利润 $20.64B，同比增长 94.9%，稀释每股收益 $22.95。
Total revenue grew 44.7% year-over-year from $45.0B to $65.2B in FY2025, reflecting extraordinary demand for Lilly's incretin-based therapies for diabetes and obesity, which have rapidly become blockbuster franchises.
来源: Source: 10-K Income Statement (XBRL Financial Data)
Net income surged 94.9% to $20.6B, with diluted EPS rising 96.0% to $22.95, demonstrating significant operating leverage as revenue growth substantially outpaced cost growth.
来源: Source: 10-K Income Statement (XBRL Financial Data)
Operating cash flow increased 90.7% to $16.8B from $8.8B in the prior year, reflecting the company's highly profitable product mix and strong cash conversion, supporting continued investment in manufacturing and R&D.
来源: Source: 10-K Cash Flow Statement (XBRL Financial Data)
Total assets grew 42.9% to $112.5B, with current assets up 69.9% to $55.6B and cash & equivalents more than doubling to $7.3B, reflecting strong earnings retention and capital market activity to fund capacity expansion.
来源: Source: 10-K Balance Sheet (XBRL Financial Data)
Lilly returned $9.5B to shareholders in FY2025 through dividends ($5.4B, up 15.0%) and share buybacks ($4.1B, up 64.3%), reflecting management's confidence in sustained cash generation.
来源: Source: 10-K Cash Flow Statement (XBRL Financial Data)
The extraordinary demand for GLP-1 medicines has strained Lilly's manufacturing capacity, potentially limiting revenue upside and creating supply shortages. Lilly has committed billions in capital expenditures (investing cash outflow of $11.0B in FY2025) to expand capacity, but execution risk remains high. Delays or cost overruns in manufacturing scale-up could impair future revenue growth.
来源: Source: 10-K Balance Sheet & Cash Flow Statement (XBRL Financial Data)
A substantial portion of Lilly's revenue growth is attributable to a narrow set of incretin-based products, creating significant concentration risk. Any safety signal, label restriction, competitive displacement, or pricing pressure on these drugs could materially impact overall company performance. The rapid revenue ramp also creates a high base effect that may be difficult to sustain.
来源: Source: 10-K Income Statement (XBRL Financial Data)
Long-term debt increased 43.3% to $40.9B in FY2025, reflecting significant borrowing to fund manufacturing expansion and acquisitions. While strong operating cash flow of $16.8B provides coverage, rising interest rates or a revenue slowdown could pressure debt serviceability. The debt-to-equity ratio remains elevated relative to historical norms.
来源: Source: 10-K Balance Sheet (XBRL Financial Data)
Lilly's GLP-1 medicines carry high list prices, making them a prominent target for government drug pricing negotiations under the Inflation Reduction Act and international reference pricing policies. Mandatory price reductions could compress margins significantly given the outsized revenue contribution of these products. SG&A expenses also rose 29.1% to $11.1B, partly reflecting lobbying and market access costs.
来源: Source: 10-K Income Statement (XBRL Financial Data)
Lilly's current valuation and earnings trajectory depend heavily on continued pipeline success and the longevity of exclusivity for key products. Patent expirations or biosimilar entry for established products, combined with any late-stage pipeline failures, could create a significant earnings gap. R&D investment must remain robust to sustain long-term growth.
来源: Source: 10-K Income Statement & Cash Flow Statement (XBRL Financial Data)
FY2025 实际 EPS $7.54，分析师一致预期 $6.74，超预期 +11.9%。
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
营业收入 | $65.18B | $45.04B | +44.70% |
营业成本 | $11.05B | $8.42B | +31.29% |
净利润 | $20.64B | $10.59B | +94.90% |
每股收益（基本） | $23.00 | $11.76 | +95.58% |
每股收益（稀释） | $22.95 | $11.71 | +95.99% |
销售及管理费用 | $11.09B | $8.59B | +29.09% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
总资产 | $112.48B | $78.72B | +42.89% |
流动资产 | $55.63B | $32.74B | +69.91% |
流动负债 | $35.23B | $28.38B | +24.15% |
股东权益 | $26.54B | $14.27B | +85.92% |
现金及等价物 | $7.27B | $3.27B | +122.40% |
长期债务 | $40.87B | $28.53B | +43.26% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
经营活动现金流 | $16.81B | $8.82B | +90.67% |
投资活动现金流 | $-10.97B | $-9.3B | -17.95% |
筹资活动现金流 | $-2.21B | $1.23B | -279.92% |
股息支出 | $5.38B | $4.68B | +15.04% |
股票回购 | $4.11B | $2.5B | +64.32% |
折旧及摊销 | $2B | $1.77B | +13.02% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
净利率 | 31.7% | — | — |
净资产收益率 | 77.8% | — | — |
总资产收益率 | 18.4% | — | — |
流动比率 | $1.579 | — | — |
Pharmaceuticals 行业其他公司
Eli Lilly's revenue grew 44.7% in FY2025, rising from $45.0B to $65.2B, driven primarily by surging demand for its GLP-1 medicines Mounjaro and Zepbound. This represents one of the largest single-year revenue increases in the company's history.
The key takeaways from Lilly's FY2025 10-K are: net income nearly doubled to $20.6B (+94.9%), diluted EPS reached $22.95 (+96.0%), and operating cash flow surged to $16.8B (+90.7%). The company also returned $9.5B to shareholders through dividends and buybacks while investing heavily in manufacturing capacity expansion.
Based on the financial data, key risks for Lilly include manufacturing capacity constraints (investing cash outflows of $11.0B in FY2025), high revenue concentration in GLP-1 drugs, drug pricing policy risk from government negotiations, and elevated long-term debt of $40.9B taken on to fund expansion. A slowdown in GLP-1 demand or adverse pricing policy changes could materially impact earnings.
Yes, Eli Lilly is highly profitable with a net margin of 31.7% in FY2025, meaning it earned approximately $0.32 in net income for every dollar of revenue. Net income totaled $20.6B on revenue of $65.2B, nearly doubling from the prior year's $10.6B.
Lilly's financial health is strong but leveraged: it holds $7.3B in cash, generates $16.8B in operating cash flow, and has a current ratio of 1.58, indicating solid liquidity. However, long-term debt rose 43.3% to $40.9B, reflecting significant borrowing to fund manufacturing scale-up, which investors should monitor alongside future revenue trends.